Showing 2,041 - 2,060 results of 7,231 for search '(( significant decrease decrease ) OR ( significantly reduced decrease ))~', query time: 0.37s Refine Results
  1. 2041
  2. 2042
  3. 2043
  4. 2044
  5. 2045
  6. 2046
  7. 2047
  8. 2048
  9. 2049
  10. 2050
  11. 2051

    Difference in by Akihiro Kakimoto (343218)

    Published 2025
    “…Compared with the resting levels, the alpha/beta ratio of EEG (indicating relaxed concentration) was significantly decreased by 19% in the video-based VR and increased by 40% in the immersive VR groups (both p < 0.05). …”
  12. 2052

    Experimental protocol. by Akihiro Kakimoto (343218)

    Published 2025
    “…Compared with the resting levels, the alpha/beta ratio of EEG (indicating relaxed concentration) was significantly decreased by 19% in the video-based VR and increased by 40% in the immersive VR groups (both p < 0.05). …”
  13. 2053

    Relationship between the change in by Akihiro Kakimoto (343218)

    Published 2025
    “…Compared with the resting levels, the alpha/beta ratio of EEG (indicating relaxed concentration) was significantly decreased by 19% in the video-based VR and increased by 40% in the immersive VR groups (both p < 0.05). …”
  14. 2054
  15. 2055

    Exclusion and enrollment summary from NHANES. by Lu Han (151620)

    Published 2025
    “…Individuals under 30 showed no significant differences. A unit increase below 9.30 in Log2-PMR reduced HCV risk by 0.60-fold. …”
  16. 2056
  17. 2057
  18. 2058

    Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

    Published 2024
    “…<b>c</b> Further addition of bevacizumab to serum samples post-bevacizumab administration significantly decreased VEGF-A121 levels in samples to which 20 and 200 μg/mL bevacizumab was added (ANOVA: <i>p</i> < 0.0001; Dunnett’s multiple comparisons test: +2 μg/mL, <i>p</i> = 0.7096 vs control; +20 μg/mL, <i>p</i> = 0.0107 vs control; +200 μg/mL, <i>p</i> < 0.0001 vs control). …”
  19. 2059
  20. 2060

    Anthelmintics Derived from the Kinase Inhibitor SGI-1776 for the Treatment of Gastrointestinal Worm Infections by Mostafa A. Elfawal (22430138)

    Published 2025
    “…We demonstrate the efficacy of optimized compound <b>50</b> as a new oral anthelmintic, which demonstrated better gut restriction properties and significantly reduced the fecundity of T. muris whipworm adults in infected mice. …”